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Abstract
Background: NF-κB is one of the key transcription factors in the inflammatory response, transactivates a series of
pro-inflammatory genes and is therefore regarded as an important target for anti-inflammatory drug screening.
Method: We recombined the reporter gene vector with inserting the “neo” transcript into the vector pNF-κB-SEAP,
made the reporter gene vector stable in a eukaryotic cell line. The recombinant reporter gene vector we named
pNF-κB-SEAP-Neo was transfected into RAW264.7. We selected the transfected RAW264.7 cell line with G418 for
15 days and then get RAW264.7 cells stably expressing NF-κB-dependent SEAP named as RAW264.7-pNF-κB-SEAP
cells. We treated the RAW264.7-pNF-κB-SEAP cells with NF-κB agonists as LPS, PolyI:C and TNF-α, NF-κB inhibitor as
PDTC and BAY117085, in different concentrations and time points and tested the expression of the SEAP,
constructed the drug screening system on the base of the RAW264.7-pNF-κB-SEAP cell line. 130 chemicals were
screened with the drug screening system we constructed and one of these chemicals numbered w10 was found
could inhibit the NF-κB significantly. At last, we verified the inhibition of w10 to expression of genes promoted with
NF-κB in HepG2 and Hela, and to migration of Hela.
Result: In this study, we established a drug screening system based on RAW264.7 cells that stably expressed the
NF-κB-dependent, SEAP reporter gene. To develop a standard method for drug screening using this reporter-gene
cell line, the test approach of SEAP was optimized and basic conditions for drug screening were chosen. This
included the initial cell number inoculated in a 96-well plate, the optimum agonist, inhibitor of NF-κB pathway and
their concentrations during screening. Subsequently, 130 newly synthesized compounds were screened using the
stable reporter-gene cell line. The anti-inflammatory effects of the candidate compounds obtained were further
verified in 2 cancer cell lines. The results indicated that compound W10 (methyl 4-(4-(prop-2-yn-1-ylcarbamoyl)
phenylcarbamoyl) benzoate) significantly inhibited SEAP production under the screening conditions. Further results
confirmed that the precursor compound significantly inhibited the transcription of NF-κB target genes.
Conclusion: In conclusion, RAW264.7 cells, stably expressing the NF-κB-dependent SEAP-reporter gene, may
provide a new, feasible, and efficient cellular drug-screening system.
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Background
Inflammation is a defence response to infection, injury,
and/or stress. When acute inflammatory response is trig-
gered, it lasts for a short period and is regulated by
negative feedback signals. Dysregulation of this feedback
mechanism results in chronic inflammation, which is be-
lieved to be a key pathophysiological mechanism in vari-
ous health disorders. In metabolic syndrome, for
example, inflammation seems to be instrumental in the
pathogenesis of insulin resistance and hepatic steatosis
[1, 2], In various cancers, the inflammatory milieu pro-
vides a favourable condition for malignant cells to prolif-
erate and migrate [3].
The macrophage, which is ubiquitously-distributed,
plays an important role in inflammation. Its functions
include phagocytosis, antigen presentation and secretion
of different types of cytokines and chemokines to regu-
late inflammation. In insulin resistance associated with
metabolic syndrome, macrophages secrete proinflamma-
tory cytokines such as tumour necrosis factor (TNF)-α
and interleukin (IL)-1β [4] while in primary and meta-
static tumours, they provide a proinflammatory micro-
environment for cancer cell growth [5]. Based on their
role in inflammation, macrophage activation has been
recognized as a target for anti-inflammation therapy.
One of the signal transduction pathways involved during
macrophage activation is the nuclear factor-κB (NF-κB)
pathway.
NF-κB is a nuclear transcription factor and contains 5
subunits: c-Rel, RelA (p65), RelB, NF-κB1 (p50 and
p105), and NF-κB2 (p52 and p100) [6]. Inactive NF-κB
forms a trimer consisting of RelA, p50, and inhibitor
protein IκB in the cytoplasm. During canonical activa-
tion IκB is phosphorylated, separates from the heterodi-
mer RelA/p50 and is degraded via ubiquitination [7]. At
the same time, the phosphorylated RelA/p50 dimer
translocates into the nucleus, and binds with cis-acting
transcription elements in its target genes [8] to form a
transcription complex. NF-κB is known to activate the
transcription of more than 400 genes [9]. During acute
inflammation such as in bacterial infection, activation of
NF-κB up-regulates transcription of various cytokines
and chemokines that promote the inflammatory re-
sponse and antigen presentation; while during chronic
inflammation, NF-κB triggers the transcription of more
complicated genes that are involved in growth, trans-
formation, and survival of cells [10]. Another difference
between acute and chronic inflammation is that NF-κB
is activated for short and long periods, respectively [11].
In both, metabolic syndrome and cancer, NF-κB is acti-
vated continuously to promote transcription of several
proinflammatory cytokines [12]. NF-κB also up-regulates
proliferation and migration of tumour cells [6] and plays
a major role in the inflammatory microenvironment of
the tumour [3]. Besides being a direct trigger and regula-
tor of the inflammatory response, NF-κB is itself regu-
lated through crosstalk with other intracellular signalling
pathways [13]. Therefore, macrophages and NF-κB are
both considered as important cellular and molecular
screening targets for anti-inflammation and anti-cancer
drugs [14].
In drug screening, the strategy strikingly depends on
the target choice and the assay method [15]. Recently,
molecules of the signalling pathway have become new
target choices for drug screening. Compared with target-
ing cellular receptors, signal pathway molecules repre-
sent the activation or inhibition of a compound within
the signal pathway more directly, thus requiring identifi-
cation of the mechanism of action of the screened com-
pound. Regarding assay methods, secreted alkaline
phosphatase (SEAP) is extensively used in the detection
of positive candidates [16]. The gene encoding SEAP has
been used as a reporter gene in screening and its activity
is represented by SEAP-expression yield. SEAP catalyses
p-nitrophenyl phosphate (PNPP) into 4-NPP, transform-
ing to yellow and soluble quinones with maximum ab-
sorption wavelength at 405 nm [17]. Thus, SEAP activity
can be measured in terms of concentration of quinones
produced in presence of SEAP. SEAP has several advan-
tages as a reporter gene for drug screening: feasibility of
application within the culture supernatant, high stability
at 65 °C, and prolonged half-life [18].
In this study, we constructed a drug screening system
targeting the NF-κB pathway in macrophages. We pro-
duced a recombinant pNF-κB-SEAP vector, transfected
mouse macrophages, and obtained a cell line stably ex-
pressing the reporter gene. We optimized conditions for
the SEAP test and basic conditions of recombined cell
culture and treatment with well-known activators and
inhibitors of the NK-κB pathway. A total of 130 newly-
synthesized compounds were screened using this drug
screening system and 8 compounds displayed striking
inhibitory activity for SEAP. Compound W10 was se-
lected to evaluate the screening results in HeLa and
HepG 2 cells, and the results showed that W10 signifi-
cantly inhibited the expression of NF-κB targeting genes.
Methods
Recombination of vector pNF-κB-SEAP
To recombine the vector pNF-κB-SEAP to be stable in
eukaryocyte, we analysed the vector sequence (http://
www.addgene.org) and found that there are 2 restriction
sites (SalI and AfeI) downstream of the SEAP transcript.
The vector pEGFP-N1 (Clontech) includes the sequence
of neomycin resistance gene “neo”. Therefore, the open
reading frame for “neo” was first amplified (forward pri-
mer: 5′-GCGTCGACGTCCTGAGGCGGAAAGAA-3′;
reverse primer: 5′-CCAGCGCTGGGGTATGTAGGC
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GGTGCTAC-3′) at 71 °C annealing temperature, for
35 cycles. Subsequently, the 2024-bp target fragment
and the vector pNF-κB-SEAP were digested with the re-
striction enzymes SalI and AfeI (Fermentas) and then
joined by T4 DNA ligase (TAKARA) (Fig. 1a). Lastly,
the recombinant plasmid, pNF-κB-SEAP-Neo, was se-
quenced (Beijing Genomics Institute).
Establishment of RAW264.7 cells stably expressing NF-κB-
dependent SEAP reporter gene
RAW264.7 cells obtained from the Cell Bank of the
Chinese Academy of Sciences (Shanghai, China),were
cultured in RPMI 1640 medium (Hyclone) with 10%
heat-inactivated foetal bovine serum (FBS; Hyclone) at
37 °C under 5% CO2 and passaged every 2 days. At the
third passage, the cells were inoculated into 6-well plates
with 1 × 106 per well and cultured overnight until the
cells reached 80%–90% confluence. The plasmid pNF-
κB-SEAP-Neo was extracted with an Endo free Plasmid
Mini preparation Kit (Omega) and its concentration was
determined using a Nanodrop (Thermo Fisher) spectro-
photometer. The extracted pNF-κB-SEAP-Neo was
transfected into RAW264.7 cells using Fugene® HD
Transfection Reagent (Promega). To form the transfec-
tion complex, the medium was removed from the wells
and 2 mL fresh RPMI 1640 medium was added. Follow-
ing this, 2 μg plasmid and 8 μL Transfection Reagent
diluted in 100 μL RPMI 1640 medium without serum
were mixed for 1 s and added to the wells in a drop-wise
manner, swirled to ensure that the transfection complex
covered the entire plate surface, and incubated for
15 min at room temperature.
After transfection with pNF-κB-SEAP-Neo plasmid for
24 h, RAW264.7 cells were selected with 200 μg/
mL G418 (Ameresco). Fresh medium containing 200 μg/
mL G418 was replenished every other day, for 15 days.
The positive clones of RAW264.7-pNF-κB-SEAP cells
were cultured and proliferated in RPMI 1640 medium
with 10% FBS and 200 μg/mL G418, at 37 °C under 5%
CO2, and designated as RAW264.7-pNF-κB-SEAP cells.
Alkaline phosphatase activity assay
Pure CIAP (Takara) was serially diluted in ultrapure-
water to obtain a series: 0.8 × 10-2, 1.6 × 10-2, 2.4 × 10-2,
3.2 × 10-2, and 4.0 × 10-2 U/mL. The substrate reaction
buffer was prepared by dissolving PNPP (Sigma-Aldrich)
in 1 mg/mL diethanolamine (DEA) buffer (0.1moL/L
DEA, 1moL/L MgCl2, pH 9.8). Subsequently, 50 μL sub-
strate was mixed with 50 μL standard alkaline phosphat-
ase solution and left to react at 37 °C for 30 min in the
dark. The microplate was then placed in an ice-bath to
end the reaction. The absorbance of the product was
read at 405 nm (OD405) and ultrapure-water is used to
adjust zero, using a full-wavelength microplate reader
Fig. 1 Recombined reporter gene vector pNF-κB-SEAP-Neo. a Schematic diagram of the recombined reporter gene vector pNF-κB-SEAP-Neo. The ORF
of eukaryotic/ prokaryotic resistance gene NeoR/KanR was amplified from pEGFP-N1 vector and inserted into pNF-κB-SEAP vector between 2 restriction
sites of SalI and AfeI to construct the recombined vector pNF-κB-SEAP-Neo. b Identification of recombined reporter gene vector pNF-κB-SEAP-Neo.
Double-restriction-enzyme digestion analysis of SalI and AfeI was performed with 1% agarose gel electrophoresis. Lane 1 is the 1-kb ladder marker.
Lane 2 is the restriction enzyme-digested products of the reporter gene vector pNF-κB-SEAP. Lane 3 is the restriction enzyme-digested products of
amplified “Neo” transcript. Lane 4 is the restriction enzyme-digested products of the recombined reporter gene pNF-κB-SEAP-Neo
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(Thermo). Taking OD405 as the abscissa and CIAP activ-
ity as the ordinate, a standard curve for SEAP activity
was obtained.
When analysing SEAP activity in the culture super-
natant, we collected the culture supernatant (150 μL per
well) and heated it at 65 °C for 5 min to inactivate other
alkaline phosphatases in the cells and the serum, and
mixed 50 μL culture supernatant with 50 μL substrate
reaction buffer at 37 °C and left it to react for 30 min in
the dark. The microplates were then placed in an ice-
bath to end the reaction. Absorbance of the product was
read at 405 nm (OD405) and fresh medium without
SEAP was used to adjust zero, using a full-wavelength
microplate reader (Thermo). The absorbance was con-
sidered directly proportional to the activity of SEAP in
the cell supernatant.
Optimizing the drug screening system with RAW264.7-
pNF-κB-SEAP
To determine the optimum number of cells in the initial
inoculum for drug screening, the cells were inoculated
in a 96-well plate at concentrations of 10,000, 20,000,
40,000, 80,000 and 160,000 cells/well, cultured for 8 h,
and incubated in 150 μL/well of high-glucose DMEM
without phenol red (Hyclone) and with or without lipo-
polysaccharide (LPS) (100 ng/mL) for 24 h. SEAP activ-
ity in the culture supernatant was measured by
microplate spectrometry.
To determine a suitable NF-κB agonist for RAW264.7-
pNF-κB-SEAP cells, the cells were treated with NF-κB
pathway agonists such as LPS, PolyI:C, and TNF-α at
different concentrations. SEAP activity in the culture
supernatant was measured at different time points using
microplate spectrometry.
The optimal quantity of RAW264.7-pNF-κB-SEAP cell
inoculum was added to a 96-well plate and cultured in
high-glucose DMEM without phenol red at 37 °C and
5% CO2 for 8 h. The cells were then treated for 24 h
with 0.1, 1, 10, or 100 ng/mL LPS (Sigma-Aldrich); 1,
10, or 100 μM PolyI:C (Amacia); 1, 10, or 100 ng/mL
TNF-α (Peprotech); or in the absence of an agonist as
the control. Following this, the concentrations of SEAP
in the samples and control were determined and relative
expression of SEAP (fold) was calculated using the
equation:
The relative expression of SEAP foldð Þ
¼ SEAP concentration in the sample
SEAP concentration inthe control
Similarly, after inoculation in a 96-well plate and incu-
bated in high-glucose DMEM without phenol red at 37 °C
and 5% CO2 for 8 h, the cells were treated with 100 ng/mL
LPS, 10nM PolyI:C, or 10 ng/mL TNF-α for 6, 12, or 24 h,
or without any agonist as the control. SEAP concentration
in the samples and control were determined and the rela-
tive activity of SEAP (fold) was calculated using the above
equation.
To determine a NF-κB inhibitor positive control for the
drug screening system, RAW264.7-pNF-κB-SEAP cells
were treated with NF-κB inhibitors pyrrolidinedithiocar-
bamate (PDTC) [19] or (2E)-3-[[4-(1,1-Dimethylethyl)
phenyl] sulfonyl]-2-propenenitrile (BAY117085) [20].
After the cells were inoculated in a 96-well plate and
cultured with high-glucose DMEM without phenol red
at 37 °C and 5% CO2 for 2 h, RAW264.7-pNF-κB-SEAP
cells with the optimal quantity of inoculum were treated
with PDTC (Beyotime) and BAY117085 (Beyotime) at
the concentrations of 0.1, 1, 10, and 100 μM for 6 h or
with 1‰ DMSO (v/v) for 6 h as the control. Then, they
were cultured in high-glucose DMEM without phenol
red containing 100 ng/mL LPS for 24 h. SEAP concen-
trations in the samples and control were determined and
the relative expression of SEAP (fold) was calculated
using the above equation.
The screening compounds
Using our established system, we screened several
series of compounds, including compounds labelled W
(N-(prop-2-ynyl)-4-(substituted phenylcarbonylamino)
benzamides) [21], compounds labelled K (2-arylisoqui-
noline-1, 3(2H, 4H)-diones [22], compounds labelled
Z (N-aryl salicylamides) [23], compounds labelled X
(diaryl urea) [24], and compounds labelled S (5-(2-
aminobenzo[d] hiazole-6-yl)-2-methoxy-3-(phenylsul-
fonylamino) benzamides) [25].
Our final screened compound W10 was synthesised as
follows. To the solution of methyl 4-(chlorocarbonyl)
benzoate (0.60 g, 3 mmol) in anhydrous THF (10 ml), a
solution of 4-amino-N-(prop-2-yn-1-yl) benzamide
(0.20 g, 1 mmol) and diisopropylethylamine (1.00 ml,
0.006 mol) in anhydrous THF (10 ml) was added drop-
wise at 0 °C. The reaction mixture was then stirred for
3.5 h at room temperature. After evaporating the solv-
ent, the residue was dissolved in ethyl acetate (20 ml).
The mixture was washed with water, followed by wash-
ing with 1 M sodium hydroxide, 1 M diluted hydrogen
chloride, and brine; dried over sodium sulphate; and fil-
tered. The filtrate was evaporated under reduced pres-
sure to afford a white solid of 0.21 g. A yield of 67.0%
was obtained. W10 is methyl 4-((4-(prop-2-ynylcarba-
moyl) phenylcarbamoyl) benzoate with its melting point
between 240 °C and 242 °C. 1H-NMR (400 MHz,
DMSO-d6): δ 10.66 (s, 1H), 8.87 (s, 1H), 8.10 (s, 4H),
7.89 (s, 4H), 4.06 (s, 2H), 3.90 (s, 3H), 3.13 (s, 1H).
HRMS m/z Calculated for C19H17N2O4 [M +H] +
337.1188, found 337.1178 [21].
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Screening of 130 compounds to find NF-κB inhibitors and
verification of the inhibitory effect of the screened com-
pound (W10)
After RAW264.7-pNF-κB-SEAP cells at the optimal in-
oculum concentration were added to 96-well plates and
cultured in high-glucose DMEM without phenol red at
37 °C and 5% CO2 for 2 h, these cells were treated with
each of the 130 compounds at the concentration of
10 μM for 6 h or with 1‰ DMSO (v/v) for 6 h as the
control. The cells were then cultured in high-glucose
DMEM without phenol red, containing 100 ng/mL LPS
for 24 h. Lastly, SEAP concentration in the samples and
control was calculated and the inhibition ratio of com-
pounds to NF-κB was determined using the following
equation:
Inhibitory ratio %ð Þ ¼ 1−relative activity of SEAPð Þ
 100
We tested the inhibitory effect of W10 on the transcrip-
tion of genes promoted by NF-κB in tumour cell lines
where NF-κB is known to be continuously activated.
HepG 2 and HeLa cell lines obtained from the Cell Bank
of the Chinese Academy of Sciences (Shanghai, China)
were chosen for this purpose. After inoculation in 6-well
plates at a concentration of 3 × 105 cells/well and incuba-
tion in high-glucose DMEM at 37 °C with 5% CO2 for
12 h, HepG 2 and HeLa cells were each, treated with 10-5
M W10, 10-5M PDTC or 1‰ DMSO (v/v) for 24 h or
48 h respectively. We extracted total RNA from these
samples and tested the transcription of cyclooxygenase
(COX)-2, monocyte chemoattractant protein (MCP) 1,
and intercellular adhesion molecule (ICAM) 1, which are
known to be promoted by NF-κB.
Scratch assay
We inoculated Hela cells at a concentration of 3 × 105
cells/well in 6-well plate and incubated in high-glucose
DMEM at 37 °C with 5% CO2 for 12 h, marking off in
the cells with 10 μL tip as straight as possible. The Hela
cells with mark-off line were treated with 1‰ DMSO (v/
v) and 10-5 M W10 in high-glucose DMEM without FBS
for 24 h or 48 h respectively. The scratches in cells were
observed and photographed with inverted microscope
(Nikon Eclipse Ri) at 24 h and 48 h. The 3 fixture posi-
tions were selected then photographed and measured
width of the scratches at the positions at 24 h and 48 h,
statistical the variation of scratches width.
Real-time quantitative polymerase chain reaction
Total RNA from the samples was extracted with TriPure
Isolation Reagent (Roche) as follows: After removing the
medium, 1 mL reagent was added into each well, incu-
bated for 5 min, and then transferred to a fresh 1.5-mL
Eppendorf tube, where chloroform (0.2 ml per 1 ml of
TriPure) was added. Then, the tubes were vortexed for
mixing, followed by centrifugation at 12,000 g and 4 °C
for 15 min till the liquid separated into 3 phases. The
aqueous phase was transferred carefully to a new tube,
mixed with an equal volume of isopropanol, vibrated
gently, and incubated at -20 °C overnight to precipitate
RNA. The mixture was centrifuged at 12,000 g and 4 °C
for 15 min; then, isopropanol was discarded and 75%
ethanol was added. The mixture was subjected to gentle
vibration and centrifuged again at 12,000 g and 4 °C for
15 min. The ethanol was then removed and placed at
room temperature until the RNA was dry and then re-
trieved with 10 μL diethylpyrocarbonate in water. The
quantity of the RNA was estimated using a Nanodrop
(Thermo Fisher) spectrophotometer.
Using RNA from the samples as template, cDNA was
prepared and amplified (First Strand cDNA Synthesis
Kit, Thermo). The amplification system included 5 μg
total RNA and 1 μL oligo (dT) primer, and the total vol-
ume made up to 12 μL with water. This system was in-
cubated at 65 °C for 5 min, cooled quickly on ice and
the following reagents were added to a final volume of
20 μL: 4 μL 5× Reaction Buffer, 1 μL RiboLock RNase
Inhibitor (20U/μL), 2 μL dNTP Mix (10 mM), and 1 μL
RevertAid M-MuLV RT (200U/μL). The amplification
mixture was mixed gently, centrifuged instantaneously,
and incubated at 42 °C for 60 min. The whole amplifica-
tion reaction was terminated at 70 °C for 5 min.
In HeLa and HepG 2 cell lines, the transcription of genes
encoding MCP1, COX-2, and ICAM1 was detected using
real-time quantitative polymerase chain reaction (RT-
qPCR), with iQ5 (Bio-Rad, Hercules, USA) and FastStart
Universal SYBR Green Master (ROX) (Roche) for 40 cycles.
The relative gene expression normalized by β-actin was cal-
culated by the 2-ΔΔCT method. Details of the primers used
are shown in Additional file 1: Table S1.
Statistics
All experiments were repeated 3 times, with 3 replicates
per analysis. Significance of difference between samples
and control was determined using the 1 way-ANOVA.
All raw values were transformed with EXCEL 2010 and
statistical analysis was performed using Prism 6.0
software.
Results
Establishment of RAW264.7-pNF-κB-SEAP cells stably
expressing NF-κB-dependent SEAP reporter gene
The reporter gene vector (Clontech) is a transient-
transfection plasmid and does not contain the eukaryotic
resistant gene for stable transfection. Therefore, it is not
suitable for establishment of the drug screening system
(Fig. 1a). There are 2 restriction sites (SalI and AfeI)
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Fig. 2 (See legend on next page.)
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downstream of the SEAP transcript in the vector pNF-
κB-SEAP. We amplified the fragment of neomycin resist-
ance geneNeoR/KanR ORF and TK-PA-terminator in
the vector pEGFP-N1,inserted the fragment into down-
stream of SEAP transcript of pNF-κB-SEAP (Fig. 1a).
The amplified fragment was 2,042 bp long (Fig. 1b).
Both pNF-κB-SEAP and the amplified fragment were
digested with SalI and AfeI (Fig. 1b) and then linked to
construct the recombinant SEAP reporter gene vector
(pNF-κB-SEAP-Neo) (Fig. 1a and b). The positive re-
combinant including pNF-κB-SEAP-Neo was selected on
Luria Bertani agar with ampicillin and then proliferated
in order to extract endotoxin-free plasmid for eukaryotic
transfection. DNA sequencing showed that there was no
mutation in the amplified fragment of the recombinant
vector pNF-κB-SEAP-Neo.
The extracted pNF-κB-SEAP-Neo was transfected into
RAW264.7 cells. By selection with fresh medium con-
taining 200 μg/mL G418for 15 days,the RAW264.7 cells
stably expressing the SEAP reporter gene (RAW264.7-
pNF-κB-SEAP cells) were established.
Alkaline phosphatase activity assay
SEAP reporter gene expression is indicated by its activ-
ity; therefore, the concentration of SEAP was deter-
mined as its activity per unit volume. Since there is a
high level of similarity between SEAP and calf intestine
alkaline phosphatase (CIAP), the standard curve of
SEAP activity was prepared using CIAP. In the standard
curve, the abscissa denotes different concentrations of
the standard substance, CIAP; the ordinate denotes
OD405, indicating the activity of alkaline phosphatase
under different concentrations of CIAP (Fig. 2a and
Additional file 2). Since CIAP is highly similar to SEAP
except for the signal peptide, the ordinate denotes
OD405, it also reflects the activity of alkaline phosphatase
under different concentrations of SEAP. The equation of
standard curve is y = 0.000315x and R2 = 0.9947.
Therefore, SEAP activity in the culture supernatant can
be calculated using this standard curve or equation using
their OD405 values.
Construction of a drug screening system based on the
recombined cell line, RAW264.7-pNF-κB-SEAP
In order to select the optimal initial inoculum of cells
for anti-inflammatory drug screen, the activity of SEAP
in culture supernatant of the RAW264.7-pNF-κB-SEAP
cells with different inocula per cell was determined in
the presence or absence of LPS (100 ng/mL) for 24 h.
The results showed that the relationship between the
log2 of initial inoculum and OD405 was consistent with
the agonist dose-response curve, when the initial inocu-
lum ranged from 20,000 to 160,000cells/well (Fig. 2b
and Additional file 2). Furthermore, when the initial in-
oculum was 40,000cells/well, the OD405 in the presence
of LPS was significantly higher than that in the absence
of LPS. Therefore, we selected 40,000 cells of
RAW264.7-pNF-κB-SEAP cells/well in a 96-well plate
for subsequent experiments. The relationship between
log2 of initial inoculum and OD405 was consistent with
the agonist-response curve as well, which further indi-
cated that the RAW264.7-pNF-κB-SEAP cells were suc-
cessfully established, stable, and can be applied to the
screening of NF-κB-dependent anti-inflammatory
compounds.
To activate NF-κB in this cell model, we treated the
RAW264.7-pNF-κB-SEAP cells with 3 NF-κB pathway ag-
onists: LPS, TNF-α, and polyI:C for 24 h. The results
showed that there was no difference after TNF-α treat-
ment (Additional file 1: Figure S1A and Additional file 2),
while SEAP secretion was significantly up-regulated after
treatment with 10nM polyI:C (Additional file 1: Figure
S1B and Additional file 2) and 10 and 100 ng/mL LPS
(Fig. 2c and Additional file 2), compared with the control
(DMSO group). We found that the relation between exci-
tation ratio of SEAP expression and the concentration of
(See figure on previous page.)
Fig. 2 Identification of standard screening method based on RAW264.7 Cell line stably expressing NF-κB-dependent SEAP reporter Gene. a Stand-
ard curve of alkaline phosphatase, y = 0.0315x, R2 = 0.9947. b Relationship between OD405 and cell number/well of Raw264.7 cells stably express-
ing NF-κB dependent SEAP reporter gene (RAW264.7-pNF-κB-SEAP cells)treated with or without LPS. R2 = 0.9395 (the cells were treated with LPS),
and R2 = 0.9910 (the cells were treated without LPS). c The effect of RAW264.7-pNF-κB-SEAP cells were treated with different concentrations of
LPS for 24 h menifested as column chart of relative activity of SEAP and dose-response stimulation curve with common logarithm of LPS concen-
tration as the ordinate and the stimulation ratio (%) as the abscissa, R2 = 0.9643. d The RAW264.7-pNF-κB-SEAP cells were treated with PDTC at
concentrations of 0.1, 1, 10, and 100 μM or 1‰ DMSO (v/v) (as control) for 6 h and then treated with LPS in 100 ng/mL for 24 h. The effect of
PDTC on RAW264.7-pNF-κB-SEAP cells was manifested as column chart of relative activity of SEAP and the dose-response inhibition curve be-
tween the log10 concentrations of PDTC and the inhibition ratio calculated from SEAP relative activity, R
2 = 0.9802, their relation according to the
common logarithmic equation. e The RAW264.7-pNF-κB-SEAP cells were treated with BAY117085 at concentrations of 0.1, 1, 10, and 50 μM or
1‰ DMSO (v/v) (as control) for 6 h and then treated with LPS in 100 ng/mL for 24 h. The effect of BAY117085 on RAW264.7-pNF-κB-SEAP cells
was manifested as column chart of relative activity of SEAP and the dose-response inhibition curve between the log10 concentrations of
BAY117085 and the inhibition ratio calculated from SEAP relative activity, R2 = 0.9735, their relation according to the common logarithmic equa-
tion. The “*” indicates that the column had significant difference compared with the control, the others marked as “#” and “^” indicate that the
column showed significant difference compared with the column on the left
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Table 1 The inhibition ratio of the 130 chemicals
Compound No. Inhibition ratio (%) Compound No. Inhibition ratio (%) Compound No. Inhibition ratio (%)
w1 -11.65 ± 1.29 k26 -14.74 ± 2.00 z4 -44.29 ± 19.53
w2 -23.07 ± 8.68 k27 -16.02 ± 1.17 z5 -39.52 ± 17.50
w3 -9.38 ± 1.53 k28 1.64 ± 3.12 z6 -19.94 ± 3.85
w4 -2.92 ± 2.03 k30 -14.45 ± 3.33 z7 -35.50 ± 16.85
w5 -12.74 ± 2.48 k32 -13.99 ± 2.33 z8 -29.85 ± 15.10
w6 -6.40 ± 2.60 k34 6.06 ± 2.06 z9 -35.72 ± 16.32
w7 2.21 ± 3.22 k35 -9.43 ± 2.00 z10 -13.67 ± 11.87
w8 4.85 ± 5.55 k36 4.81 ± 8.98 z11 -21.48 ± 7.93
w9 6.41 ± 7.79 k37 -4.56 ± 0.75 z12 -22.78 ± 7.29
W10 27.20 ± 5.91*** k38 -6.22 ± 1.40 z13 -38.60 ± 16.45
w11 12.99 ± 0.34** k33 -4.24 ± 3.08 z14 -42.24 ± 19.10
w12 4.49 ± 8.32 k40 -4.84 ± 0.62 z15 -9.32 ± 10.93
w13 -2.24 ± 2.98 x1 -10.09 ± 0.37 z16 -17.9 ± 13.51
w14 -2.85 ± 2.72 x2 -13.39 ± 0.83 z17 -16.95 ± 15.87
w15 42.95 ± 28.87* x3 -6.83 ± 2.87 z18 -10.58 ± 10.06
w19 15.76 ± 5.56** x4 -9.21 ± 3.05 z19 6.12 ± 6.76
w20 29.82 ± 10.13** x5 -2.57 ± 1.20 z20 -13.51 ± 4.73
w21 -10.04 ± 1.59 x6 -8.41 ± 0.48 z21 -4.97 ± 4.55
w22 -12.64 ± 4.55 x8 -3.20 ± 0.43 z22 -2.92 ± 4.35
w23 -12.17 ± 3.76 x9 9.43 ± 1.85* s1 15.23 ± 1.85**
k1 -8.45 ± 3.57 x10 -4.75 ± 0.60 s2 6.82 ± 1.28
k2 -2.86 ± 1.86 x11 -3.74 ± 0.85 s3 26.57 ± 6.43***
k3 -5.10 ± 1.92 x12 -3.49 ± 0.63 s4 10.68 ± 3.97*
k4 -11.37 ± 3.07 x13 -6.20 ± 9.91 s5 -0.58 ± 3.33
k5 -4.99 ± 1.116 x14 -14.30 ± 9.40 s6 -3.90 ± 6.65
k6 -2.10 ± 1.52 x15 -20.12 ± 16.57 s7 -11.21 ± 2.75
k7 -4.36 ± 2.82 x16 -37.86 ± 6.55 s8 -14.82 ± 6.92
k8 -2.22 ± 3.39 x17 -31.71 ± 2.97 s9 -9.54 ± 3.42
k9 -6.56 ± 2.32 x18 -41.94 ± 8.21 s10 -23.73 ± 7.42
k10 -4.30 ± 2.47 x19 -26.51 ± 20.62 s11 -14.65 ± 5.85
k11 -3.05 ± 2.17 x20 -14.09 ± 8.09 s12 -6.06 ± 25.05
k12 5.12 ± 0.42 x21 -25.66 ± 11.07 s13 -11.09 ± 2.86
k13 8.26 ± 2.57 x22 5.25 ± 18.74 s14 -4.31 ± 2.64
k14 9.31 ± 2.81 x23 4.80 ± 1.82 s15 20.42 ± 2.62***
k15 5.30 ± 1.41 x24 7.56 ± 9.16 s16 4.57 ± 5.97
k16 12.63 ± 2.95* x25 -7.50 ± 5.60 s17 11.34 ± 1.90
k17 6.19 ± 0.75 x26 3.62 ± 5.16 s18 16.33 ± 9.43*
k18 -6.14 ± 0.96 x27 0.19 ± 3.65 s19 -5.27 ± 3.55
k20 3.80 ± 0.79 x28 11.67 ± 10.08 s20 19.63 ± 2.34***
k21 -2.91 ± 0.58 x29 -1.12 ± 8.86 s22 6.79 ± 4.18
Li et al. BMC Pharmacology and Toxicology  (2017) 18:5 Page 8 of 13
LPS was according to the excitation-response curve, R2 =
0.9643, and this result indicated that the effect of LPS on
SEAP secretion of RAW264.7-pNF-κB-SEAP cells was
dose-dependent (Fig. 2c and Additional file 2). However,
as traditional agonists to Toll-like receptor -3 and TNFR,
activation of polyI:C and TNF-α to NF-κB should be
present in this reporter gene system; therefore, we tested
for the effects of LPS, polyI:C, and TNF-α on SEAP at dif-
ferent time points. The results showed that SEAP secre-
tion was up-regulated only after treatment with 10nM
polyI:C and 10 ng/mL TNF-α for 12 h, while there was
significant up-regulation at 3 time points after treatment
with 100 ng/mL LPS, compared with their corresponding
controls (DMSO group) (Additional file 1: Figure S1C)
and Additional file 2. Therefore, the optimal agonist of
NF-κB was LPS, at 100 ng/mL with treatment duration of
24 h, respectively (Fig. 2c and Additional file 2).
In order to select a NF-κB inhibitor as positive control
in the drug screening system for anti-inflammatory com-
pounds, the RAW264.7-pNF-κB-SEAP cells were pre-
treated with NF-κB inhibitors, PDTC and BAY117085
for 6 h before treatment with 100 ng/mL LPS for 24 h.
The results showed that PDTC significantly down-
regulated SEAP secretion by these cells compared to the
control group, at concentrations ranging from 10 to
100 μM (Fig. 2d and Additional file 2), while BAY117085
significantly decreased SEAP secretion by these cells
compared to the control group at concentrations ran-
ging from 0.1 to 50 μM (Fig. 2e and Additional file 2).
Although the inhibitory effect of BAY117085 seemed to
be superior to that of PDTC, some dead cells were ob-
served with BAY117085 at concentration of 100 μM.
Therefore, PDTC was selected as the positive control in
the drug screening system for anti-inflammatory com-
pounds. In addition, as the inhibition ratio of 10 μM
PDTC was nearer to 50%, the concentration of 10 μM
PDTC was used in subsequent screening.
Thus, the drug screening system on the basis of the
RAW264.7-pNF-κB-SEAP was established. The proced-
ure of screening was as follows: the RAW264.7-pNF-κB-
SEAP cells were inoculated in the 96-well plate at a
concentration of 40,000cells/well and incubated with
high-glucose DMEM without phenol red at 37 °C for 2 h
to allow adherence. These cells were then treated with
100 ng/mL LPS for 24 h after pre-treatment with 10 μM
test compounds, 1‰ DMSO (blank control), and 10 μM
PDTC (positive control) for 6 h. The activity of SEAP in
the culture supernatant was determined. Lastly, the in-
hibitory ratio of compounds was calculated as compared
to blank control.
Screening of 130 compounds as NF-κB inhibitors using
the drug screening system and verification of the inhibi-
tory effect of the screened compound W10
Using our new drug screen system, we screened 130
compounds. The results showed that 13 compounds had
remarkable inhibitory effect on the secretion of SEAP
(Table 1 and Additional file 2). Of these, 8 compounds
(P < 0.01) (Table 1 and Additional file 2) were analysed
once again. The results showed that there was no differ-
ence in their inhibition ratio between the primary and
the repeat screens (Table 2 and Additional file 2). The
inhibition ratio of the compound W10 was stable in the
2 screenings (Table 2 and Additional file 2). In contrast,
the inhibition ratio of the compound S15 was signifi-
cantly increased in the repeat than in the primary screen
(Table 2 and Additional file 2). We chose compound
W10 to carry out subsequent studies.
The compound structure of W10 is shown in Fig. 3.
We planned for further studies on W10 at the molecular
mechanism of the compound stable inhibition on the
NF-κB. RAW264.7 cells were treated with W10 for 2 h
and then with LPS for 6, 12, and 24 h. Transcription of
Table 1 The inhibition ratio of the 130 chemicals (Continued)
k22 -0.02 ± 2.30 x30 -3.87 ± 3.32 s23 -6.96 ± 4.91
k23 1.35 ± 1.78 z1 -23.43 ± 13.80 s24 -16.02 ± 6.30
k24 -2.47 ± 2.41 z2 -28.88 ± 17.48 PDTC 50.35 ± 1.36
k25 -4.87 ± 1.48 z3 -19.87 ± 11.88
The result showed as the format of “Mean ± SEM”
The “*” means that the column had significant difference compared with the control, P < 0.05; **P < 0.01; and ***P < 0.001
Table 2 Comparison of inhibition ratio of 8 chemicals between





Inhibition ratio(%) from 2nd
screening
w10 27.20 ± 5.91 26.64 ± 1.41
w11 12.99 ± 0.34 23.96 ± 6.22
w19 15.76 ± 5.57 12.44 ± 1.08
w20 29.82 ± 10.13 7.73 ± 1.18
s1 15.23 ± 1.85 10.12 ± 1.24
s3 26.57 ± 6.43 20.35 ± 0.86
s15 20.42 ± 2.62 41.90 ± 0.55
s20 19.63 ± 2.34 22.52 ± 0.81
PDTC 40.97 ± 1.32 52.07 ± 3.45
The results showed as the format of”Mean ± SEM”
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COX-2 and IL6 was activated by NF-κB. The result
showed that the transcription of COX-2 and IL6 was up-
regulated by LPS, but W10 did not inhibit their up-
regulation induced by LPS (Additional file 1: Figure S2
and Additional file 2). The transcription of COX-2,
ICAM1 and MCP1 was significantly inhibited in HepG 2
cells after treatment with W10 for 24 h, whereas, tran-
scription inhibition by MCP1 remained for only 48 h
(Fig. 4a, b, and c and Additional file 2). The transcrip-
tion of COX-2 and ICAM1 was significantly inhibited in
HeLa cells after treatment with W10 for 24 h and this
inhibition remained for 48 h. Additionally, the transcrip-
tion of MCP1 was significantly inhibited in HeLa cells
after treatment with W10 for 48 h (Fig. 4d, e, and f and
Additional file 2). As the transcription of ICAM1 and
MCP1 were inhibited with W10, we detected whether
W10 inhibited the migration of tumour cells with
scratch testing. The results showed that the scratches in
HeLa cells were significant narrow down in control
group for 24 h and 48 h. However, the scratches in HeLa
cells have not vary significantly for 24 h and 48 h in
W10 treated group (Fig. 4g and h and Additional file 2).
Discussion
The most important parameter for a drug screening
system is stability. To this end, we constructed a stable
recombinant cell line, selected a reporter gene with a
prolonged half-life, used standard detection methods
for the reporter gene, and selected an optimal agonist
and inhibitor for this system. Although a drug screen-
ing system based on instantaneous transfection of
reporter gene has been previously reported, we con-
structed a stable reporter gene recombinant cell line,
since transfection of the RAW264.7 cell line selected
for this system is a challenge. We constructed a stable
reporter gene recombinant cell line to provide a foun-
dation for stability of the screening system. Similarly,
while selecting the reporter gene, we chose SEAP ra-
ther than luciferase, which is otherwise popular in
drug screening methods. Due to its sensitivity and ease
of detection, luciferase is suited to testing cells in
which a transcription promoter is momentarily acti-
vated or inhibited [26]. However, signal pathway acti-
vation and cascade mechanisms vary. For example,
persistent effect as seen with LPS activating NF-κB
through binding with TLR4, pulsating effect as seen
with TNF-α activating NF-κB through binding with
TNFR [27], feedback effect as seen with HDL inhibit-
ing proinflammatory gene transcription by activating
ATF3 [28]. These effects occur in different periods
and are difficult to detect in a single test based on lu-
ciferase. Other than the instant effect, we focused on
the complete effect of the compound on cells within a
period, therefore we chose the reporter gene SEAP
which has a longer half-life and lower distinguishing
ability, to construct the drug screen system [29]. For
SEAP testing, we established a standard curve of alka-
line phosphatase activity that improves the stability of
the drug screening system. The standard curve of alka-
line phosphatase activity translates the screening re-
sults into absolute, quantified values and provides
uniformity to the screening results from different time
points. In the screening process, we chose an optimal
agonist and inhibitor of NF-κB to treat the reporter
gene recombinant cell line. LPS was found to signifi-
cantly induce NF-κB activation for a long period
(24 h). The significant up-regulation of SEAP expres-
sion was sustained throughout this period. This
persistent and significant activation of NF-κB authen-
ticates the inhibitory effect of the candidate com-
pounds and diminishes false-negative error. PDTC is
recognized as a typical NF-κB inhibitor. This was
chosen as the optimal inhibitor of NF-κB in our drug
screening system. During screening, we treated cells
with PDTC at the same concentration as candidate
compounds, which was near to the IC50 of PDTC for
NF-κB. While the samples treated with PDTC were
taken as positive control, we could gauge whether in-
hibition of SEAP expression by PDTC skewing the re-
sults indicated if the cells are unusually sensitive due
to age, mutation or other reasons. PDTC as positive
control compound helped ensure that the drug screen-
ing system was stable. Besides, we tested the inhibition
of NF-κB by the compound W10 with RT-qPCR,
which showed that W10 inhibited transcription of
genes regulated by NF-κB and the inhibition of W10
remained for 48 h. Testing and verification of tran-
scription of genes promoted by NF-κB is working for
maintaining stability of the drug screening system.
After screening 130 compounds using the system, we
Fig. 3 The structure of w10. Methyl 4-((4-(prop-2-ynylcarbamoyl) phenylcarbamoyl) benzoate (w10)
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evaluated stability of the system in terms of ease to
operate and perform the test, while maintaining
control.
From our study, we found that W10 did not inhibit the
transcription of genes downstream of NF-κB activated by
LPS; rather, W10 inhibited the transcription of genes
downstream of the NF-κB signal in tumour cell lines that
NF-κB persistently activated, and part of the inhibitory ef-
fect persisted until 48 h. These results indicated that W10
is specific to NF-κB. LPS induces gene transcription not
only via NF-κB; W10 specifically inhibited the up-
regulation of genes from NF-κB. Therefore, W10 did not
inhibit the up-regulation of genes induced by the LPS sig-
nal on the whole. This phenomenon shows that the drug
Fig. 4 The effectsto HepG2 and HeLa cellstreated with W10 in relative gene and scratches. The relative expression level of COX-2 (a), ICAM1 (b),
and MCP1 (c) in HepG 2 cells after treatment with control, PDTC, or W10 for 24 or 48 h. The relative expression level of COX-2 (d), ICAM1 (e), and
MCP1 (f) in HeLa cells after treatment with control, PDTC, or W10 for 24 or 48 h. The width of scratchesin Hela cells after treatment with control
and W10 for 24 h or 48 h expressed in photograph (g) and histogram (h). The data are expressed as mean ± SEM from 3 independent experiments.
The “*” indicates that the column had significant difference compared with the control in group
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screening system we constructed is highly specific to its
target and therefore, W10 can be allied to cancer research
and therapy.
Conclusion
We constructed a drug screening system targeting the
transcription factor NF-κB, based on the cell line
RAW264.7. In this drug screening system, unstable fac-
tors were eliminated by standardizing each index and
choosing the optimal control, which increased the stabil-
ity and accuracy of the drug screening system, allowing
for a simple and fast assay. The compound W10 were
selected with the drug screening system we constructed.
In our further studies, W10 was detected to inhibit the
transcription of COX-2, ICAM1 and MCP1 in Hela and
HepG2 and inhibit the migration of Hela cells.
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